CYP2D6 is primarily responsible for the metabolism of clomiphene.

Ghobadi C, Gregory A, Crewe HK, Rostami-Hodjegan A, Lennard MS

Drug metabolism and pharmacokinetics1 Jan 2008Cited by 18 (Europe PMC)

PMID18445989DOI10.2133/dmpk.23.101PepBankPUB-18445989

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

3 results from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cell-free)Pharmacokinetics
In microsomal tests, extensive-metabolizer liver microsomes and recombinant CYP2D6 metabolized enclomiphene, with 40-60% drug disappearance.
In plain wordsIn lab tests, liver microsomes from extensive metabolizers and recombinant CYP2D6 metabolized enclomiphene, with 40-60% drug disappearance.
Peptide
Enclomiphene
Outcome
DecreaseMetabolism by extensive-metabolizer and recombinant microsomes
Study
humann: not reported in source
Human liver microsomes and recombinant CYP2D6 microsomes
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
25 microMAs given in this study (human).
Measurements
Drug disappearance
40 to 60%
extensive-metabolizer and recombinant CYP2D6 microsomes
Source sentences
Summary
Microsomes from all the EM livers and recombinant CYP2D6 metabolised enclomiphene (the disappearance of drug ranged from 40-60%).
1 context sentence(design, population, supporting numbers)
Summary · context
Enclomiphene (25 microM) was incubated with human liver microsomes (from 4 extensive (EM) and 1 poor metaboliser with respect to CYP2D6) and with microsomes from lymphoblastoid cells expressing CYP2D6.
Report a problemFND-1844598901
02LabIn vitro (cell-free)Pharmacokinetics
In microsomal tests, no enclomiphene metabolism was detected in the poor-metabolizer liver sample.
In plain wordsIn lab tests, liver microsomes from a poor metabolizer did not detectably metabolize enclomiphene.
Peptide
Enclomiphene
Outcome
No significant changeMetabolism in poor-metabolizer microsomes
Study
humann: not reported in source
Human liver microsomes from a CYP2D6 poor metaboliser
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
25 microMAs given in this study (human).
Source sentences
Summary
No metabolism was detected in microsomes from the PM liver.
1 context sentence(design, population, supporting numbers)
Summary · context
Enclomiphene (25 microM) was incubated with human liver microsomes (from 4 extensive (EM) and 1 poor metaboliser with respect to CYP2D6) and with microsomes from lymphoblastoid cells expressing CYP2D6.
Report a problemFND-1844598902
03LabIn vitro (cell-free)Mechanism
In microsomal tests, the extent of enclomiphene metabolism correlated with CYP2D6 abundance.
In plain wordsIn lab tests, enclomiphene metabolism was linked to the amount of CYP2D6.
Peptide
Enclomiphene
Outcome
Direction not reportedMetabolism correlation with CYP2D6 amount
Study
humann: not reported in source
Human liver microsomes and recombinant CYP2D6 microsomes
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
25 microMAs given in this study (human).
Source sentences
Summary
The extent of enclomiphene metabolism was correlated with the amount of CYP2D6 present (p<0.001, Pearson correlation test).
1 context sentence(design, population, supporting numbers)
Summary · context
Enclomiphene (25 microM) was incubated with human liver microsomes (from 4 extensive (EM) and 1 poor metaboliser with respect to CYP2D6) and with microsomes from lymphoblastoid cells expressing CYP2D6.
Report a problemFND-1844598905

Studies that did not test the peptide alone2

In this study, Enclomiphene was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Enclomiphene.

04LabNot a test of Enclomiphene aloneIn vitro (cell-free)Pharmacokinetics
In microsomal tests, quinidine completely inhibited enclomiphene metabolism in extensive-metabolizer liver and recombinant CYP2D6 microsomes.
In plain wordsIn lab tests, quinidine completely blocked enclomiphene metabolism in extensive-metabolizer liver and recombinant CYP2D6 microsomes.
Peptide
Enclomiphene
Outcome
DecreaseQuinidine inhibition of metabolism
Study
humann: not reported in source
Human liver microsomes and recombinant CYP2D6 microsomes
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
Quinidine (1 microM) completely inhibited the metabolism of enclomiphene by all the EM livers and by recombinant CYP2D6 (p<0.001, one way ANOVA).
1 context sentence(design, population, supporting numbers)
Summary · context
Enclomiphene (25 microM) was incubated with human liver microsomes (from 4 extensive (EM) and 1 poor metaboliser with respect to CYP2D6) and with microsomes from lymphoblastoid cells expressing CYP2D6.
In this study, Enclomiphene was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Enclomiphene.
Report a problemFND-1844598903
05LabNot a test of Enclomiphene aloneIn vitro (cell-free)Pharmacokinetics
In microsomal tests, ketoconazole did not significantly affect enclomiphene metabolism in three of four extensive-metabolizer livers.
In plain wordsIn lab tests, ketoconazole did not significantly change enclomiphene metabolism in three of four extensive-metabolizer livers.
Peptide
Enclomiphene
Outcome
No significant changeKetoconazole effect on metabolism
Study
humann: not reported in source
Human liver microsomes from CYP2D6 extensive metabolisers
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
Ketoconazole (2 microM) had no significant effect on enclomiphene metabolism in 3 out of the 4 EM livers.
1 context sentence(design, population, supporting numbers)
Summary · context
Enclomiphene (25 microM) was incubated with human liver microsomes (from 4 extensive (EM) and 1 poor metaboliser with respect to CYP2D6) and with microsomes from lymphoblastoid cells expressing CYP2D6.
In this study, Enclomiphene was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Enclomiphene.
Report a problemFND-1844598904

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.